52 research outputs found
Mental and Physical Health and Intimate Partner Violence against Women: A Review of the Literature
Associations between intimate partner violence (IPV) and poor physical and mental health of women have been demonstrated in the international and national literature across numerous studies. This paper presents a review of the literature on this topic. The 75 papers included in this review cover both original research studies and those which undertook secondary analyses of primary data sources. The reviewed research papers published from 2006 to 2012 include quantitative and qualitative studies from Western and developing countries. The results show that while there is variation in prevalence of IPV across various cultural settings, IPV was associated with a range of mental health issues including depression, PTSD, anxiety, self-harm, and sleep disorders. In most studies, these effects were observed using validated measurement tools. IPV was also found to be associated with poor physical health including poor functional health, somatic disorders, chronic disorders and chronic pain, gynaecological problems, and increased risk of STIs. An increased risk of HIV was reported to be associated with a history of sexual abuse and violence. The implications of the study findings in relation to methodological issues, clinical significance, and future research direction are discussed
Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
Disease fatality associated with Ebola, SARS-CoV and dengue infections in humans is attributed to a cytokine storm that is triggered by excessive pro-inflammatory responses. Interleukin (IL)-6 acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signaling, respectively. Hence, IL-6 is assumed to provide a target for a broad range of antiviral agents. Available immunosuppressive antivirals are directed to control an often exaggerated pro-inflammatory response that gives rise to complex clinical conditions such as lymphocytopenia. It is known that IL-6, via its soluble receptor (sIL-6R), initiates a pro-inflammatory response while an anti-inflammatory response is triggered by the membrane-bound IL-6 receptor (IL-6R). Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling. In this review, we propose that the tumour necrosis factor-α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes
Migrant Populations: Socio-cultural Dynamics and the Explanation for the Risk of HIV/AIDS Transmission in Bangladesh
Several studies reported premarital and extra-marital sex in Bangladesh society, including among migrant workers. Some studies documented extra-marital sex among the wives of the migrant workers, confirmed prevalence of HIV among migrant workers' families and transmission of HIV from migrant workers to their wives and children. However, most of these studies concentrated on risky behaviors and knowledge about HIV/AIDS. The social and cultural factors that may shape the risk behaviours of migrant workers and their wives while they live away from each other have largely been ignored. Against this backdrop, the present research aimed to understand and explain the factors associated with risky sexual behaviours of the wives of the migrants and non-migrant workers and their vulnerability to HIV infection. The research particularly focused on the socio-economic factors, and the religious-cultural context that could influence the risk behaviours of migrant and non-migrant men and wives of the migrant men in a rural area in Bangladesh. The present research consists of two components: (i) a descriptive, quantitative part that analyses a secondary data set on the wives of migrants and non-migrant workers, and (ii) an exploratory, qualitative component that probes the socio-cultural issues from in-depth interviews with migrant and non-migrant men and wives of the migrant and non-migrant men
Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies
Purpose: The increased number of outbreaks of H5 and H7 LPAI and
HPAI viruses in poultry has major public and animal health implications.
The continuous rapid evolution of these subtypes and the emergence
of new variants influence the ability to undertake effective surveillance.
Retroviral pseudotypes bearing influenza haemagglutinin (HA) and
neuraminidase (NA) envelope glycoproteins represent a flexible platform
for sensitive, readily standardized influenza serological assays.
We describe a multiplex assay for the study of neutralizing antibodies
that are directed against both influenza H5 and H7 HA. This assay
permits the measurement of neutralizing antibody responses against
two antigenically distinct HAs in the same serum/plasma sample thus
increasing the amount and quality of serological data that can be
acquired from valuable sera.
Methods & Materials: Sera obtained from chickens vaccinated
with a monovalent H5N2 vaccine, chickens vaccinated with a bivalent
H7N1/H5N9 vaccine, or turkeys naturally infected with an H7N3 virus
were evaluated in the pseudotype assay (simple and multiplex format).
Results: The results obtained using the pseudotype-based assays
correlated strongly with data obtained by HI assay. We show that pseudotypes
are highly stable under basic cold-chain storage conditions
and following multiple rounds of freeze-thaw.
Conclusion: We propose that this robust assay may have practical
utility for in-field serosurveillance and vaccine studies in resource-limited
regions worldwide
Kinetic investigation of hydroxide ion and DNA attack on some high spin iron (II) chelates Bearing ONO Donors amino acid Schiff bases
The reactivity of few novel high spin Fe(II) complexes of Schiff base ligands derived from 2-hydroxynaphthaldehyde and some variety of amino acids with OH- ion has been examined in aqueous mixture at temperature in the range 10–40 Co. Based on the kinetic investigations, the rate law and a plausible mechanism were proposed and discussed. The general rate equation was suggested as follows: rate = kobs [Complex], where kobs.= k1 + k2 [OH-]. Base catalyzed hydrolysis kinetics measurements imply pseudo-first order doubly stage rates due the presence of merand fac-isomers. The observed rate constants kobs are correlated the effect of substituent R in the structure of the ligands. From the effect of temperature on the rate; various thermodynamic parameters have been evaluated. The evaluated rate constants and activation parameters are in a good agreement with the stability constants of the investigated complexes
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study
Summary
Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally.
Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies
have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of
the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income
countries globally, and identified factors associated with mortality.
Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to
hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis,
exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a
minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical
status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary
intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause,
in-hospital mortality for all conditions combined and each condition individually, stratified by country income status.
We did a complete case analysis.
Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital
diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal
malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome
countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male.
Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3).
Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income
countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups).
Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome
countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries;
p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients
combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11],
p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20
[1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention
(ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety
checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed
(ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of
parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65
[0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality.
Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome,
middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will
be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger
than 5 years by 2030
Kinetic investigation of hydroxide ion and DNA attack on some high spin iron (II) chelates Bearing ONO Donors amino acid Schiff bases
The reactivity of few novel high spin Fe(II) complexes of Schiff base ligands derived from 2-hydroxynaphthaldehyde and some variety of amino acids with OH- ion has been examined in aqueous mixture at temperature in the range 10–40 Co. Based on the kinetic investigations, the rate law and a plausible mechanism were proposed and discussed. The general rate equation was suggested as follows: rate = kobs [Complex], where kobs.= k1 + k2 [OH-]. Base catalyzed hydrolysis kinetics measurements imply pseudo-first-order doubly stage rates due the presence of merandfac-isomers. The observed rate constants kobs are correlated the effect of substituent R in the structure of the ligands.From the effect of temperature on the rate; various thermodynamic parameters have been evaluated. The evaluated rate constants and activation parameters are in a good agreement with the stability constants of the investigated complexes.Keywords: Base catalyzed hydrolysis, Isomer, Reaction mechanism, Thermodynamic parameters
Influence of rurality on intimate partner violence in young Australian women
Intimate partner violence (IPV) is a major public health issue in both developed and developing countries. IPV has been identified as a significant contributor to the burden of disease through its association with physical and mental ill-health, both in the short term, and in the long term through chronic health conditions. In developed countries, such as Australia, much of the research into IPV has been conducted in metropolitan settings. There is however a growing body of research, primarily from the USA, indicating that women living in non-metropolitan areas may experience differences in type, severity and prevalence of IPV compared to metropolitan women. To date there has been limited Australian research into aspects of IPV for women living outside major metropolitan centres. This thesis aimed to address this gap in the Australian IPV research by investigating differences in women's experiences of IPV across metropolitan, regional and more remote areas of Australia. This study used quantitative techniques to conduct a secondary analysis of data from the Australian Longitudinal Study on Women's Health (ALSWH), a national population-based health survey that provides longitudinal data for the sixteen year period from 1996 to 2012. This thesis specifically focuses on the ALSWH cohort of women born between 1973-78. This cohort of over 14,000 women was first surveyed in 1996 when their mean age was 21 years. Through the ALSWH, this cohort of women has been surveyed every three years and, to date, there have been six surveys, most recently in 2012, when the mean age of the cohort was 36 years. This thesis presents statistical analyses into geographic differences in five aspects of IPV, namely: lifetime prevalence of IPV, past 12 month prevalence and type of IPV, association of IPV and domestic relocation, IPV and self-reported health, and IPV and health service use
- …